Clinical Styles and Practice Policies: Influence on Communication with Patients Regarding Worrisome Prescription Drug Monitoring Program Data

Christi Hildebran, Gillian Leichtling, Jessica M. Irvine, Deborah Cohen, Sara E. Hallvik, Richard (Rick) Deyo

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

OBJECTIVES: Clinician communication with patients regarding worrisome findings in Prescription Drug Monitoring Programs (PDMPs) may influence patient responses and subsequent care. The authors studied the range of approaches clinicians report when communicating with patients in this situation and how practice policies and procedures may influence this communication.

DESIGN: Qualitative interviews of clinician PDMP users.

SETTING: Oregon registrants in the state's PDMP.

SUBJECTS: Thirty-three clinicians practicing in pain management, emergency medicine, primary care, psychiatry, dentistry, and surgery.

METHODS: The authors conducted semi-structured interviews via telephone with clinicians who routinely used the PDMP. A multidisciplinary team used a grounded theory approach to identify ways clinicians reported using information from the PDMP when communicating with patients, and policies that influenced that communication.

RESULTS: Clinicians reported using a range of approaches for communicating about PDMP results, from openly sharing, to questioning patients without disclosing access to the PDMP, to avoiding the conversation. Clinicians also reported practice policies and procedures that influenced communication with their patients about prescribing and ongoing care, including policies that normalized use of the PDMP with all patients and those that facilitated difficult conversations by providing a rationale not to prescribe in certain circumstances.

CONCLUSION: Clinicians' self-reported approaches to sharing PDMP findings and communicating prescribing decisions with patients vary and may be facilitated by appropriate practice policies. Such communication may have implications for patient engagement and alliance building. More research is needed to identify best practices and potential guidelines for effectively communicating about PDMP findings, as this may enhance health outcomes.

Original languageEnglish (US)
Pages (from-to)2061-2066
Number of pages6
JournalPain medicine (Malden, Mass.)
Volume17
Issue number11
StatePublished - Nov 1 2016

Fingerprint

Prescription Drugs
Drug Monitoring
Communication
Practice Guidelines
Interviews
Patient Participation
Emergency Medicine
Pain Management
Dentistry
Psychiatry
Primary Health Care

Keywords

  • Doctor-Patient Communication
  • PDMP
  • Policy
  • Prescription Drug Abuse

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Clinical Styles and Practice Policies : Influence on Communication with Patients Regarding Worrisome Prescription Drug Monitoring Program Data. / Hildebran, Christi; Leichtling, Gillian; Irvine, Jessica M.; Cohen, Deborah; Hallvik, Sara E.; Deyo, Richard (Rick).

In: Pain medicine (Malden, Mass.), Vol. 17, No. 11, 01.11.2016, p. 2061-2066.

Research output: Contribution to journalArticle

@article{ba67642c753e4ab4a49806c2bb7cdc09,
title = "Clinical Styles and Practice Policies: Influence on Communication with Patients Regarding Worrisome Prescription Drug Monitoring Program Data",
abstract = "OBJECTIVES: Clinician communication with patients regarding worrisome findings in Prescription Drug Monitoring Programs (PDMPs) may influence patient responses and subsequent care. The authors studied the range of approaches clinicians report when communicating with patients in this situation and how practice policies and procedures may influence this communication.DESIGN: Qualitative interviews of clinician PDMP users.SETTING: Oregon registrants in the state's PDMP.SUBJECTS: Thirty-three clinicians practicing in pain management, emergency medicine, primary care, psychiatry, dentistry, and surgery.METHODS: The authors conducted semi-structured interviews via telephone with clinicians who routinely used the PDMP. A multidisciplinary team used a grounded theory approach to identify ways clinicians reported using information from the PDMP when communicating with patients, and policies that influenced that communication.RESULTS: Clinicians reported using a range of approaches for communicating about PDMP results, from openly sharing, to questioning patients without disclosing access to the PDMP, to avoiding the conversation. Clinicians also reported practice policies and procedures that influenced communication with their patients about prescribing and ongoing care, including policies that normalized use of the PDMP with all patients and those that facilitated difficult conversations by providing a rationale not to prescribe in certain circumstances.CONCLUSION: Clinicians' self-reported approaches to sharing PDMP findings and communicating prescribing decisions with patients vary and may be facilitated by appropriate practice policies. Such communication may have implications for patient engagement and alliance building. More research is needed to identify best practices and potential guidelines for effectively communicating about PDMP findings, as this may enhance health outcomes.",
keywords = "Doctor-Patient Communication, PDMP, Policy, Prescription Drug Abuse",
author = "Christi Hildebran and Gillian Leichtling and Irvine, {Jessica M.} and Deborah Cohen and Hallvik, {Sara E.} and Deyo, {Richard (Rick)}",
year = "2016",
month = "11",
day = "1",
language = "English (US)",
volume = "17",
pages = "2061--2066",
journal = "Pain Medicine",
issn = "1526-2375",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Clinical Styles and Practice Policies

T2 - Influence on Communication with Patients Regarding Worrisome Prescription Drug Monitoring Program Data

AU - Hildebran, Christi

AU - Leichtling, Gillian

AU - Irvine, Jessica M.

AU - Cohen, Deborah

AU - Hallvik, Sara E.

AU - Deyo, Richard (Rick)

PY - 2016/11/1

Y1 - 2016/11/1

N2 - OBJECTIVES: Clinician communication with patients regarding worrisome findings in Prescription Drug Monitoring Programs (PDMPs) may influence patient responses and subsequent care. The authors studied the range of approaches clinicians report when communicating with patients in this situation and how practice policies and procedures may influence this communication.DESIGN: Qualitative interviews of clinician PDMP users.SETTING: Oregon registrants in the state's PDMP.SUBJECTS: Thirty-three clinicians practicing in pain management, emergency medicine, primary care, psychiatry, dentistry, and surgery.METHODS: The authors conducted semi-structured interviews via telephone with clinicians who routinely used the PDMP. A multidisciplinary team used a grounded theory approach to identify ways clinicians reported using information from the PDMP when communicating with patients, and policies that influenced that communication.RESULTS: Clinicians reported using a range of approaches for communicating about PDMP results, from openly sharing, to questioning patients without disclosing access to the PDMP, to avoiding the conversation. Clinicians also reported practice policies and procedures that influenced communication with their patients about prescribing and ongoing care, including policies that normalized use of the PDMP with all patients and those that facilitated difficult conversations by providing a rationale not to prescribe in certain circumstances.CONCLUSION: Clinicians' self-reported approaches to sharing PDMP findings and communicating prescribing decisions with patients vary and may be facilitated by appropriate practice policies. Such communication may have implications for patient engagement and alliance building. More research is needed to identify best practices and potential guidelines for effectively communicating about PDMP findings, as this may enhance health outcomes.

AB - OBJECTIVES: Clinician communication with patients regarding worrisome findings in Prescription Drug Monitoring Programs (PDMPs) may influence patient responses and subsequent care. The authors studied the range of approaches clinicians report when communicating with patients in this situation and how practice policies and procedures may influence this communication.DESIGN: Qualitative interviews of clinician PDMP users.SETTING: Oregon registrants in the state's PDMP.SUBJECTS: Thirty-three clinicians practicing in pain management, emergency medicine, primary care, psychiatry, dentistry, and surgery.METHODS: The authors conducted semi-structured interviews via telephone with clinicians who routinely used the PDMP. A multidisciplinary team used a grounded theory approach to identify ways clinicians reported using information from the PDMP when communicating with patients, and policies that influenced that communication.RESULTS: Clinicians reported using a range of approaches for communicating about PDMP results, from openly sharing, to questioning patients without disclosing access to the PDMP, to avoiding the conversation. Clinicians also reported practice policies and procedures that influenced communication with their patients about prescribing and ongoing care, including policies that normalized use of the PDMP with all patients and those that facilitated difficult conversations by providing a rationale not to prescribe in certain circumstances.CONCLUSION: Clinicians' self-reported approaches to sharing PDMP findings and communicating prescribing decisions with patients vary and may be facilitated by appropriate practice policies. Such communication may have implications for patient engagement and alliance building. More research is needed to identify best practices and potential guidelines for effectively communicating about PDMP findings, as this may enhance health outcomes.

KW - Doctor-Patient Communication

KW - PDMP

KW - Policy

KW - Prescription Drug Abuse

UR - http://www.scopus.com/inward/record.url?scp=85029726866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029726866&partnerID=8YFLogxK

M3 - Article

C2 - 27009292

AN - SCOPUS:85029726866

VL - 17

SP - 2061

EP - 2066

JO - Pain Medicine

JF - Pain Medicine

SN - 1526-2375

IS - 11

ER -